article thumbnail

CAFC Says District Court Committed ‘Clear Error’ in Enforcing Disputed Settlement Agreement

IP Watchdog

On appeal, the CAFC held that CNC’s version of the agreement more accurately reflected the understanding between the two parties regarding a settlement over Plasmacam’s claim that CNC infringed U.S. 7,071,441 (‘441 patent), for which Plasmacam has an exclusive license.

article thumbnail

Alvotech and Teva Reach Ustekinumab (STELARA) Settlement with J&J

LexBlog IP

announced that they reached a settlement and license agreement with Johnson & Johnson regarding AVT04, Alvotech’s proposed biosimilar to STELARA (ustekinumab) in the United States. The post Alvotech and Teva Reach Ustekinumab (STELARA) Settlement with J&J appeared first on Big Molecule Watch.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Formycon/Fresenius Kabi and Samsung Bioepis Settlements with J&J and Janssen Biotech regarding Ustekinumab

LexBlog IP

On August 7, 2023, Formycon AG and Fresenius Kabi announced that they have reached a settlement with Johnson & Johnson (“J&J”) in the United States relating to FYB202, a proposed ustekinumab biosimilar to STELARA®, marketed by J&J. Economic terms of the settlement were not disclosed in the press release.

article thumbnail

Celltrion Stelara (Ustekinumab) Settlement With J&J

LexBlog IP

It has been reported that Celltrion has finalized a settlement with Johnson & Johnson (“J&J”) in the United States relating to CT-P43, Celltrion’s ustekinumab biosimilar to J&J’s STELARA®, which would permit Celltrion to launch the product in the U.S. market on March 7, 2025, if approved by FDA.

article thumbnail

Alvotech Announces More Settlements and Expected Launch Dates Regarding Biosimilar to STELARA (ustekinumab), AVT04

LexBlog IP

On February 15, Alvotech announced that it reached more settlement agreements with Johnson & Johnson for ATV04, Alvotech’s biosimilar to STELARA (ustekinumab). Alvotech is still awaiting FDA approval of AVT04 in the United States, but has already secured a licensing agreement with Johnson & Johnson for the U.S.

article thumbnail

Roblox is Latest Online Platform to Settle NMPA Copyright Claims with Collaborative Music Licensing Agreement

IP Watchdog

The settlement also creates an opt-in mechanism for eligible NMPA publishers and opens a negotiation period for individual publishers to engage Roblox in go-forward licensing deals.

Music 104
article thumbnail

NPE Showcase – Sockeye Licensing

LexBlog IP

This installment will focus on a company named Sockeye Licensing TX, LLC. Settlement agreements are typically confidential so the exact arrangement is unclear. But what we do know is Sockeye cannot sue a defendant for activity that is already licensed. NPEs are also known to limit their license when suing software companies.